These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18593779)

  • 1. Atypical antipsychotic medications in Alzheimer's disease: effectiveness versus expectations.
    Schultz SK
    Am J Psychiatry; 2008 Jul; 165(7):787-9. PubMed ID: 18593779
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
    Schneider LS; Ismail MS; Dagerman K; Davis S; Olin J; McManus D; Pfeiffer E; Ryan JM; Sultzer DL; Tariot PN
    Schizophr Bull; 2003; 29(1):57-72. PubMed ID: 12908661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical neuroleptics as a treatment of agitation and anxiety in Alzheimer's disease: risks or benefits.
    Moretti R; Torre P; Antonello RM; Pizzolato G
    Expert Rev Neurother; 2006 May; 6(5):705-10. PubMed ID: 16734518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.
    Auchus AP; Bissey-Black C
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):591-3. PubMed ID: 9447502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic treatment of psychosis and agitation in the elderly.
    Daniel DG
    J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of the agitation of late-life psychosis and Alzheimer's disease.
    Salzman C
    Eur Psychiatry; 2001 Jan; 16 Suppl 1():25s-28s. PubMed ID: 11520475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A regulatory perspective on psychiatric syndromes in Alzheimer disease.
    Laughren T
    Am J Geriatr Psychiatry; 2001; 9(4):340-5. PubMed ID: 11739061
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly.
    Beier MT
    Am J Health Syst Pharm; 2007 Jan; 64(2 Suppl 1):S9-17; quiz S24-5. PubMed ID: 17215476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.
    Ismail MS; Dagerman K; Tariot PN; Abbott S; Kavanagh S; Schneider LS
    Curr Alzheimer Res; 2007 Jul; 4(3):325-35. PubMed ID: 17627490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicating "Margaret".
    Reid C
    J Clin Ethics; 2006; 17(4):340-3. PubMed ID: 17330727
    [No Abstract]   [Full Text] [Related]  

  • 11. Agitation and psychosis in dementia.
    Ballard C
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):913-7. PubMed ID: 17974863
    [No Abstract]   [Full Text] [Related]  

  • 12. To prescribe or not to prescribe? Atypical antipsychotic drugs in patients with dementia.
    Jeste DV; Meeks T
    South Med J; 2007 Oct; 100(10):961-3. PubMed ID: 17943030
    [No Abstract]   [Full Text] [Related]  

  • 13. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.
    Weiner MF; Tractenberg RE; Sano M; Logsdon R; Teri L; Galasko D; Gamst A; Thomas R; Thal LJ
    J Geriatr Psychiatry Neurol; 2002; 15(2):95-8. PubMed ID: 12083600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
    Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
    Omerovic M; Hampel H; Teipel SJ; Buerger K
    World J Biol Psychiatry; 2008; 9(1):69-75. PubMed ID: 17886162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease.
    Raskind MA
    J Clin Psychiatry; 1998; 59 Suppl 9():28-32. PubMed ID: 9720484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options.
    Lesser JM; Hughes S
    Geriatrics; 2006 Dec; 61(12):14-20. PubMed ID: 17184138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of music therapy on reducing agitation in patients with Alzheimer's disease, a pre-post study.
    Zare M; Ebrahimi AA; Birashk B
    Int J Geriatr Psychiatry; 2010 Dec; 25(12):1309-10. PubMed ID: 21086543
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases: evidence about efficacy and safety.
    Weintraub D; Katz IR
    Psychiatr Clin North Am; 2005 Dec; 28(4):941-83, ix-x. PubMed ID: 16325736
    [No Abstract]   [Full Text] [Related]  

  • 20. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.
    Gleason RP; Schneider LS
    J Clin Psychiatry; 1990 Mar; 51(3):115-8. PubMed ID: 1968457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.